| Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter JJ Eron, SL Benoit, J Jemsek, RD MacArthur, J Santana, JB Quinn, ... New England Journal of Medicine 333 (25), 1662-1669, 1995 | 664 | 1995 |
| Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 S Naggie, C Cooper, M Saag, K Workowski, P Ruane, WJ Towner, ... New England Journal of Medicine 373 (8), 705-713, 2015 | 568 | 2015 |
| Bone disease in HIV infection: a practical review and recommendations for HIV care providers GA McComsey, P Tebas, E Shane, MT Yin, ET Overton, JS Huang, ... Clinical infectious diseases 51 (8), 937-946, 2010 | 488 | 2010 |
| Detection of KPC in Acinetobacter spp. in Puerto Rico IE Robledo, EE Aquino, MI Santé, JL Santana, DM Otero, CF León, ... Antimicrobial agents and chemotherapy 54 (3), 1354-1357, 2010 | 338 | 2010 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 219 | 2018 |
| Diagnostic usefulness of brief versions of Alcohol Use Disorders Identification Test (AUDIT) for detecting hazardous drinkers in primary care settings. A Gomez, A Conde, JM Santana, A Jorrin Journal of studies on alcohol 66 (2), 305-308, 2005 | 148 | 2005 |
| A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of … KE Squires, R Gulick, P Tebas, J Santana, V Mulanovich, R Clark, ... Aids 14 (11), 1591-1600, 2000 | 121 | 2000 |
| Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults F Raffi, C Orkin, A Clarke, L Slama, J Gallant, E Daar, K Henry, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 75 (2), 226-231, 2017 | 100 | 2017 |
| A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV‐specific immunizations, and interleukin‐2 cycles to promote efficient control of viral replication … JM Kilby, RP Bucy, D Mildvan, M Fischl, J Santana‐Bagur, J Lennox, ... The Journal of infectious diseases 194 (12), 1672-1676, 2006 | 91 | 2006 |
| Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals JF Rodriguez, JL Rodriguez, J Santana, H García, O Rosario Antimicrobial agents and chemotherapy 44 (11), 3097-3100, 2000 | 75 | 2000 |
| Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069/ACTG A5305) RM Gulick, TJ Wilkin, YQ Chen, RJ Landovitz, KR Amico, AM Young, ... The Journal of infectious diseases 215 (2), 238-246, 2017 | 73* | 2017 |
| The diagnostic usefulness of AUDIT and AUDIT-C for detecting hazardous drinkers in the elderly A Gómez, A Conde, JM Santana, A Jorrín, IM Serrano, R Medina Aging and Mental Health 10 (5), 558-561, 2006 | 65 | 2006 |
| Physical and leisure activity, body composition, and life satisfaction in HIV-positive Hispanics in Puerto Rico FA Ramírez-Marrero, BA Smith, N Meléndez-Brau, JL Santana-Bagur Journal of the Association of Nurses in AIDS Care 15 (4), 68-77, 2004 | 64 | 2004 |
| Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis S Krishnan, JT Schouten, DL Jacobson, CA Benson, AC Collier, ... Oncology 80 (1-2), 42-49, 2011 | 62 | 2011 |
| Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naïve HIV-1–Infected patients: A randomized trial R Gross, C Tierney, A Andrade, C Lalama, S Rosenkranz, SH Eshleman, ... Archives of internal medicine 169 (13), 1224-1232, 2009 | 59 | 2009 |
| A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial SS Solomon, S Wagner-Cardoso, L Smeaton, LA Sowah, C Wimbish, ... The Lancet Gastroenterology & Hepatology 7 (4), 307-317, 2022 | 56 | 2022 |
| Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem … E Font, O Rosario, J Santana, H García, JP Sommadossi, JF Rodriguez Antimicrobial agents and chemotherapy 43 (12), 2964-2968, 1999 | 55 | 1999 |
| Less bone loss with maraviroc-versus tenofovir-containing antiretroviral therapy in the AIDS Clinical Trials Group A5303 Study BO Taiwo, ES Chan, CJ Fichtenbaum, H Ribaudo, A Tsibris, KL Klingman, ... Clinical Infectious Diseases 61 (7), 1179-1188, 2015 | 53 | 2015 |
| Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF–emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical … GA McComsey, ES Daar, MA O'Riordan, AC Collier, L Kosmiski, ... The Journal of infectious diseases 207 (4), 604-611, 2013 | 51 | 2013 |
| Assessment of coronary artery disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with HIV eligible for primary … U Hoffmann, MT Lu, B Foldyna, MV Zanni, J Karady, J Taron, BK Zhai, ... JAMA Network Open 4 (6), e2114923-e2114923, 2021 | 48 | 2021 |
